Fexofen Oral Suspension 30 mg/5 ml

Fexofen Oral Suspension is a non-sedating antihistamine manufactured by Somatec Pharmaceuticals Ltd, containing Fexofenadine Hydrochloride (30 mg/5 ml). Priced at ৳50.00 per unit, this oral suspension offers cost-effective relief for allergic conditions while ensuring minimal drowsiness.

This medication treats allergic rhinitis and chronic idiopathic urticaria in adults and children above 12 years. Symptoms like sneezing, itchy eyes, nasal congestion, and hives are effectively managed by blocking H1 receptors without crossing the blood-brain barrier, reducing CNS side effects.

Dosage varies by age and condition:

• Adults/children ≥12 years: 5 ml (30 mg) twice daily
• Children 2–11 years: 5 ml twice daily
• Renal impairment: Half the usual dose

Avoid antacids 2 hours before/after intake to prevent reduced efficacy.

Common side effects include headache, nausea, and dizziness. Rare but severe reactions include tachycardia or hypersensitivity. Safe use during pregnancy or lactation requires medical consultation. Store at room temperature, away from children.

Adults & 12+ years: 30mg/5ml twice daily. Children (6mo-2yrs): 2.5ml twice daily. Halve dose for renal impairment. Administer with water, avoiding concurrent antacids. Maximum treatment duration: 6 months without medical supervision.

The following frequency rating has been used, when applicable: Very common ≥1/10; Common ≥1/100 and <1/10; Uncommon ≥1/1,000 and <1/100; Rare ≥1/10,000 and <1/1,000; Very rare <1/10,000 and not known (frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. In adults, the following undesirable effects have been reported in clinical trials, with an incidence similar to that observed with placebo: Nervous system disorders- Common: headache, drowsiness, dizziness; Gastrointestinal disorders- Common: nausea; General disorders and administration site conditions- Uncommon: fatigue. In adults, the following undesirable effects have been reported in post-marketing surveillance. The frequency with which they occur is not known (cannot be estimated from available data): Immune system disorders- hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, flushing and systemic anaphylaxis; Psychiatric disorders- insomnia, nervousness, sleep disorders or nightmares/excessive dreaming (paroniria); Cardiac disorders- tachycardia, palpitations; Gastrointestinal disorders- diarrhea; Skin and subcutaneous tissue disorders- rash, urticaria, pruritus

Pregnancy Category C: Use only if potential benefit justifies risk. Contraindicated in lactation—excreted in breast milk. No teratogenic effects in animal studies.

Monitor cardiac rhythm in CVD patients. Regular renal function tests for elderly. Assess individual response before operating machinery despite low sedation risk.

Pediatrics: Age-specific dosing from 6 months. Geriatric: 50% increased bioavailability. Renal impairment: Halve dose if GFR <40. Hepatic disease: No dose adjustment needed.

Dizziness, drowsiness, fatigue and dry mouth have been reported with overdose of Fexofen. Single doses up to 800 mg and doses up to 690 mg twice daily for 1 month or 240 mg once daily for 1 year have been administered to healthy subjects without the development of clinically significant adverse reactions as compared with placebo. The maximum tolerated dose of Fexofen has not been established. Standard measures should be considered to remove any unabsorbed medicinal product. Symptomatic and supportive treatment is recommended. Haemodialysis does not effectively remove Fexofen from blood.